Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 0.6032 USD 2.2%
Market Cap: 91.9m USD
Have any thoughts about
Seres Therapeutics Inc?
Write Note

Intrinsic Value

MCRB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MCRB stock under the Base Case scenario is 0.8507 USD. Compared to the current market price of 0.6032 USD, Seres Therapeutics Inc is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MCRB Intrinsic Value
0.8507 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Seres Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MCRB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MCRB?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Seres Therapeutics Inc

Provide an overview of the primary business activities
of Seres Therapeutics Inc.

What unique competitive advantages
does Seres Therapeutics Inc hold over its rivals?

What risks and challenges
does Seres Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Seres Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Seres Therapeutics Inc.

Provide P/S
for Seres Therapeutics Inc.

Provide P/E
for Seres Therapeutics Inc.

Provide P/OCF
for Seres Therapeutics Inc.

Provide P/FCFE
for Seres Therapeutics Inc.

Provide P/B
for Seres Therapeutics Inc.

Provide EV/S
for Seres Therapeutics Inc.

Provide EV/GP
for Seres Therapeutics Inc.

Provide EV/EBITDA
for Seres Therapeutics Inc.

Provide EV/EBIT
for Seres Therapeutics Inc.

Provide EV/OCF
for Seres Therapeutics Inc.

Provide EV/FCFF
for Seres Therapeutics Inc.

Provide EV/IC
for Seres Therapeutics Inc.

Show me price targets
for Seres Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Seres Therapeutics Inc?

How accurate were the past Revenue estimates
for Seres Therapeutics Inc?

What are the Net Income projections
for Seres Therapeutics Inc?

How accurate were the past Net Income estimates
for Seres Therapeutics Inc?

What are the EPS projections
for Seres Therapeutics Inc?

How accurate were the past EPS estimates
for Seres Therapeutics Inc?

What are the EBIT projections
for Seres Therapeutics Inc?

How accurate were the past EBIT estimates
for Seres Therapeutics Inc?

Compare the revenue forecasts
for Seres Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Seres Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Seres Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Seres Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Seres Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Seres Therapeutics Inc with its peers.

Analyze the financial leverage
of Seres Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Seres Therapeutics Inc.

Provide ROE
for Seres Therapeutics Inc.

Provide ROA
for Seres Therapeutics Inc.

Provide ROIC
for Seres Therapeutics Inc.

Provide ROCE
for Seres Therapeutics Inc.

Provide Gross Margin
for Seres Therapeutics Inc.

Provide Operating Margin
for Seres Therapeutics Inc.

Provide Net Margin
for Seres Therapeutics Inc.

Provide FCF Margin
for Seres Therapeutics Inc.

Show all solvency ratios
for Seres Therapeutics Inc.

Provide D/E Ratio
for Seres Therapeutics Inc.

Provide D/A Ratio
for Seres Therapeutics Inc.

Provide Interest Coverage Ratio
for Seres Therapeutics Inc.

Provide Altman Z-Score Ratio
for Seres Therapeutics Inc.

Provide Quick Ratio
for Seres Therapeutics Inc.

Provide Current Ratio
for Seres Therapeutics Inc.

Provide Cash Ratio
for Seres Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Seres Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Seres Therapeutics Inc?

What is the current Free Cash Flow
of Seres Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Seres Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Seres Therapeutics Inc

Current Assets 149.3m
Cash & Short-Term Investments 71.2m
Receivables 18.6m
Other Current Assets 59.4m
Non-Current Assets 172.5m
PP&E 121.1m
Other Non-Current Assets 51.4m
Current Liabilities 108.3m
Accounts Payable 4.8m
Accrued Liabilities 16.6m
Other Current Liabilities 86.8m
Non-Current Liabilities 300.5m
Long-Term Debt 102.5m
Other Non-Current Liabilities 198m
Efficiency

Earnings Waterfall
Seres Therapeutics Inc

Revenue
364k USD
Operating Expenses
-155m USD
Operating Income
-154.6m USD
Other Expenses
-7.6m USD
Net Income
-162.2m USD

Free Cash Flow Analysis
Seres Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MCRB Profitability Score
Profitability Due Diligence

Seres Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

16/100
Profitability
Score

Seres Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

MCRB Solvency Score
Solvency Due Diligence

Seres Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
35/100
Solvency
Score

Seres Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MCRB Price Targets Summary
Seres Therapeutics Inc

Wall Street analysts forecast MCRB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MCRB is 3.9719 USD with a low forecast of 1.01 USD and a high forecast of 10.5 USD.

Lowest
Price Target
1.01 USD
67% Upside
Average
Price Target
3.9719 USD
558% Upside
Highest
Price Target
10.5 USD
1 641% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MCRB?

Click here to dive deeper.

Dividends

Seres Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MCRB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

MCRB News

Profile

Seres Therapeutics Inc Logo
Seres Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

91.5m USD

Dividend Yield

0%

Description

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

Contact

MASSACHUSETTS
Cambridge
200 Sidney St
+16179459626.0
serestherapeutics.com

IPO

2015-06-26

Employees

333

Officers

President, CEO & Director
Mr. Eric D. Shaff M.B.A.
Executive VP & Chief Medical Officer
Dr. Lisa von Moltke M.D.
Executive VP and Chief Commercial & Strategy Officer
Dr. Teresa L. Young Ph.D., R.Ph.
Executive VP & CFO
Ms. Marella Thorell
Executive VP & Chief Technology Officer
Dr. David S. Ege Ph.D.
Executive VP & Chief Scientific Officer
Dr. Matthew R. Henn Ph.D.
Show More
Investor Relations Officer
Mr. Carlo Tanzi Ph.D.
Chief Legal Officer, Executive VP & Secretary
Mr. Thomas J. DesRosier Esq., J.D.
Assistant General Counsel
Ms. Caroline Holda
Show Less

See Also

Discover More
What is the Intrinsic Value of one MCRB stock?

The intrinsic value of one MCRB stock under the Base Case scenario is 0.8507 USD.

Is MCRB stock undervalued or overvalued?

Compared to the current market price of 0.6032 USD, Seres Therapeutics Inc is Undervalued by 29%.

Back to Top